Genetic polyendocrinopathy

Genetic polyendocrinopathy is a broad grouping term used in Orphanet (ORPHA:183643) to classify inherited conditions in which multiple endocrine glands are affected simultaneously due to underlying genetic causes. These disorders involve dysfunction of two or more endocrine organs, which may include the parathyroid glands, adrenal glands, thyroid gland, pancreatic islets, pituitary gland, and gonads. The clinical presentation varies widely depending on the specific syndrome but commonly includes features such as hypoparathyroidism, adrenal insufficiency, thyroid dysfunction, diabetes mellitus, and gonadal failure. Patients may also experience mucocutaneous candidiasis, autoimmune manifestations, or other organ-specific complications depending on the underlying genetic defect. This category encompasses several well-characterized conditions, including autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, also known as APS type 1, caused by mutations in the AIRE gene), as well as other monogenic forms of multiple endocrine neoplasia and polyendocrine deficiency syndromes. Because this is a classification grouping rather than a single disease entity, the inheritance pattern, age of onset, and specific symptoms depend on the individual condition within this category. Management is typically directed at replacing deficient hormones (such as corticosteroids, thyroid hormone, insulin, or sex steroids), treating autoimmune complications, managing infections like chronic candidiasis, and providing regular surveillance for the development of additional endocrine and non-endocrine manifestations. Early diagnosis through genetic testing can facilitate anticipatory care and improve long-term outcomes.

Common questions about Genetic polyendocrinopathy